Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

uniQure Added to NASDAQ Biotechnology Index

uniQure N.V.
Posted on: 11 Dec 17

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 11, 2017 (GLOBE NEWSWIRE) --  uniQure N.V.  (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company has been added to the NASDAQ Biotechnology Index (NBI). The addition is part of NBI's annual review of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market that meet NBI's eligibility criteria. uniQure will be added to the NBI effective prior to market open on Monday, December 18, 2017. 

The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market, that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark and is re-ranked annually in December.  Additional information on the eligibility criteria and further details about the index are available through  this link .

About uniQure  
uniQure is delivering on the promise of gene therapy -- single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and cardiovascular diseases.  www.uniQure.com

uniQure Contacts:

Maria E. Cantor
Direct: 339-970-7536 
Mobile:  617-680-9452
m.cantor@uniqure.com

Eva M. Mulder   
Direct: +31 20 240 6103 
Mobile: +31 6 52 33 15 79
e.mulder@uniQure.com

Tom Malone
Direct:  339-970-7558
Mobile:  339-223-8541
t.malone@uniQure.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: uniQure N.V. via GlobeNewswire
HUG#2155386
GlobeNewswire
globenewswire.com

Last updated on: 12/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.